Neuren Pharmaceuticals Limited

Informe acción ASX:NEU

Capitalización de mercado: AU$1.7b

Neuren Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos y los beneficios de Neuren Pharmaceuticals disminuyan a un ritmo anual de 2.6% y 9.9% respectivamente. Se espera que el BPA disminuya en un 14.1% al año. Se prevé que la rentabilidad financiera sea de 19% en 3 años.

Información clave

-9.9%

Tasa de crecimiento de los beneficios

-14.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals46.2%
Tasa de crecimiento de los ingresos-2.6%
Rentabilidad financiera futura19.0%
Cobertura de analistas

Good

Última actualización18 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29
Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Nov 11
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Nov 08
Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Oct 24
Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29
Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Aug 14
Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31
Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03
Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01
An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05
Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02
Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18
Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02
Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31
Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31
Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03
We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06
Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19
Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04
Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Previsiones de crecimiento de beneficios e ingresos

ASX:NEU - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2026209109103885
12/31/202511458115876
12/31/202419411336695
6/30/2024193117119120N/A
3/31/2024213137152152N/A
12/31/2023232157185185N/A
9/30/2023155106120120N/A
6/30/202378555454N/A
3/31/202347282929N/A
12/31/202215044N/A
9/30/20229-3-3-3N/A
6/30/20223-7-10-10N/A
3/31/20223-7-10-10N/A
12/31/20213-8-10-10N/A
9/30/20212-10-10-10N/A
6/30/20211-12-9-9N/A
3/31/20211-11-9-9N/A
12/31/20201-9-8-8N/A
9/30/20201-8-9-9N/A
6/30/20200-8-9-9N/A
3/31/20200-9-10-10N/A
12/31/20190-11-12-12N/A
9/30/20197-6-5-5N/A
6/30/201914-122N/A
3/31/201914144N/A
12/31/201814366N/A
9/30/20187300N/A
6/30/201813-6-6N/A
3/31/201813N/A-6N/A
12/31/201713N/A-6N/A
9/30/20172-2N/A-7N/A
6/30/20173-8N/A-8N/A
3/31/20173-10N/A-10N/A
12/31/20163-12N/A-12N/A
9/30/20162-14N/A-14N/A
6/30/20160-15N/A-17N/A
3/31/20161-14N/A-15N/A
12/31/20152-13N/A-13N/A
9/30/20152-11N/A-11N/A
6/30/20153-9N/A-8N/A
3/31/20153-9N/A-7N/A
12/31/20143-8N/A-6N/A
9/30/20143-10N/A-7N/A
6/30/20143-12N/A-7N/A
3/31/20144-11N/A-7N/A
12/31/20135-10N/A-7N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de NEU disminuyan en los próximos 3 años (-9.9% al año).

Beneficios vs. Mercado: Se prevé que los beneficios de NEU disminuyan en los próximos 3 años (-9.9% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de NEU disminuyan en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de NEU disminuyan en los próximos 3 años (-2.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de NEU disminuyan en los próximos 3 años (-2.6% al año).


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de NEU sea baja dentro de 3 años (19%).


Descubre empresas en crecimiento